FILE:JNJ/JNJ-8K-20070418113221.txt.gz
EVENTS:	Results of Operations and Financial Condition	Regulation FD Disclosure	Financial Statements and Exhibits
TEXT:
ITEM: Results of Operations and Financial Condition
ITEM: Regulation FD Disclosure
ITEM: Financial Statements and Exhibits
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2007 JOHNSON & JOHNSON (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or other Commission (I.R.S. Employer jurisdiction File Number) Identification No.) of incorporation) One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (Address of principal executive offices) (zip code) Registrant's telephone number including area code: (732) 524-0400 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) Item 2.02 Results of Operations and Financial Condition On April 17, 2007, the Company issued supplemental tables of sales of key products/franchises to its press release announcing the Company's sales and earnings for the first quarter ended April 1, 2007. These tables appear in Exhibit 99.1 to this report and are incorporated herein by reference. In addition, the press release reported operational sales growth rates on a pro forma basis to include the net impact of the acquisition of Pfizer Consumer Healthcare. A presentation of these pro forma operational sales rates and the as reported operational sales growth rates appears in Exhibit 99.2 to this report and is incorporated herein by reference. Item 7.01 Regulation FD Disclosure. On April 17, 2007, during the first quarter 2007 earnings conference call with the investment community, the Company raised 2007 full year adjusted earnings per share guidance to a range of $4.02-$4.07*. This guidance reflects the Company's solid financial performance in the first quarter of 2007, continued cost control and the impact from its financing strategy. The guidance includes the impact of the dilutive effect, excluding in- process research & development, of the acquisition of Conor Medsystems, Inc., which was completed in February 2007. The Company also increased guidance for 2007 full year operational sales growth to between 12.0% and 12.5%. *Adjusted earning per share excludes in-process research and development charges, as well as other special items. (This report contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.) Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Sales of Key Products/Franchises 1Q 2007 99.2 Presentation of Pro Forma Operational Sales Growth Rates SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JOHNSON & JOHNSON (Registrant) Date: April 18, 2007 By: /s/ Stephen J. Cosgrove Stephen J. Cosgrove Controller (Principal Accounting Officer)

Exhibit 99.1 JOHNSON & JOHNSON REPORTED SALES vs. PRIOR PERIOD (Unaudited, Dollars in Millions) First Quarter % Change 2007 2006 Reported Operational* Currency CONSUMER SEGMENT (1) OTC/Nutritional US $ 655 445 47.3% 47.3 - Intl 602 208 188.8 182.3 6.5 WW 1,257 653 92.5 90.4 2.1 Skin Care US 357 318 12.4 12.4 - Intl 407 341 19.2 13.1 6.1 WW 764 659 16.0 12.8 3.2 Baby & Kids Care US 109 103 5.5 5.5 - Intl 338 303 11.5 6.8 4.7 WW 447 406 9.9 6.4 3.5 Women's Health US 163 148 10.3 10.3 - Intl 258 251 2.8 (2.3) 5.1 WW 421 399 5.6 2.5 3.1 Oral Care US 203 55 270.2 270.2 - Intl 156 38 306.0 301.8 4.2 WW 359 93 285.0 283.3 1.7 Other US 142 81 74.6 74.6 - Intl 106 64 65.9 61.1 4.8 WW 248 145 71.4 69.3 2.1 Total Consumer Segment US 1,629 1,150 41.7 41.7 - Intl 1,867 1,205 54.9 49.4 5.5 WW $3,496 2,355 48.5% 45.7 2.8 (1) 2007 includes sales from acquisition of PCH PHARMACEUTICAL SEGMENT Anti-Psychotics (2) US $ 710 585 21.4% 21.4 - Intl 468 433 7.9 1.9 6.0 WW 1,178 1,018 15.7 13.2 2.5 EPREX(R)/PROCRIT(R) US 530 527 .5 .5 - Intl 287 259 10.9 3.5 7.4 WW 817 786 3.9 1.5 2.4 REMICADE(R) (3) US 731 681 7.4 7.4 - WW 731 681 7.4 7.4 - TOPAMAX(R) US 501 373 34.4 34.4 - Intl 109 98 11.4 4.9 6.5 WW 610 471 29.7 28.4 1.3 LEVAQUIN(R)/FLOXIN(R) US 460 393 17.0 17.0 - Intl 15 10 49.7 53.4 (3.7) WW 475 403 17.8 17.9 (.1) ACIPHEX(R)/PARIET(R) US 159 146 9.1 9.1 - Intl 177 160 10.4 4.6 5.8 WW 336 306 9.8 6.8 3.0 DURAGESIC(R)/Fentanyl Transdermal US 116 110 4.8 4.8 - Intl 187 215 (12.8) (17.9) 5.1 WW 303 325 (6.8) (10.2) 3.4 CONCERTA(R) US 200 193 3.4 3.4 - Intl 52 42 25.3 17.9 7.4 WW 252 235 7.3 6.0 1.3 Hormonal Contraceptives US 174 198 (12.0) (12.0) - Intl 63 56 13.0 8.1 4.9 WW 237 254 (6.5) (7.6) 1.1 Other US 453 495 (8.4) (8.4) - Intl 829 652 27.1 20.5 6.6 WW 1,282 1,147 11.8 8.7 3.1 Total Pharmaceutical Segment US 4,034 3,701 9.0 9.0 - Intl 2,187 1,925 13.6 7.7 5.9 WW $6,221 5,626 10.6% 8.6 2.0 (2) Includes RISPERDAL(R), RISPERDAL CONSTA(R) & INVEGA(R) (3) US REMICADE(R) sales includes International Distributors of $131 Q1 2007 & $115 Q1 2006 MEDICAL DEVICES AND DIAGNOSTICS DEPUY(R) US $ 678 644 5.3% 5.3 - Intl 479 395 21.1 13.6 7.5 WW 1,157 1,039 11.3 8.4 2.9 CORDIS(R) US 424 530 (20.1) (20.1) - Intl 504 545 (7.4) (10.7) 3.3 WW 928 1,075 (13.6) (15.3) 1.7 ETHICON ENDO-SURGERY(R) US 417 380 9.8 9.8 - Intl 474 414 14.6 9.0 5.6 WW 891 794 12.3 9.4 2.9 ETHICON(R) US 344 296 16.4 16.4 - Intl 526 478 9.9 4.2 5.7 WW 870 774 12.4 8.8 3.6 LIFESCAN(R) US 292 288 1.5 1.5 - Intl 257 216 18.7 12.0 6.7 WW 549 504 8.9 6.0 2.9 Total Vision Care US 195 172 13.5 13.5 - Intl 318 269 18.2 16.3 1.9 WW 513 441 16.4 15.2 1.2 ORTHO-CLINICAL DIAGNOSTICS(R) US 219 199 10.2 10.2 - Intl 174 171 1.5 (3.1) 4.6 WW 393 370 6.2 4.1 2.1 Other US 15 11 35.6 35.6 - Intl 4 3 26.1 19.2 6.9 WW 19 14 38.6 37.8 .8 Total MD&D Segment US 2,584 2,520 2.5 2.5 - Intl 2,736 2,491 9.8 4.7 5.1 WW $5,320 5,011 6.2% 3.7 2.5 *Operational growth excludes the effect of currency

Exhibit 99.2 Johnson & Johnson 2007 Q1 As Reported and Pro-Forma Net Trade Sales Reported and Operational Growth Rates Reported Growth Pro-Forma Growth (1) Total% Oper.% Total% Oper.% Skin Care 16% 13 10% 7 Baby & Kids Care 10 6 8 5 Oral Care 285 283 13 11 OTC / Nutritionals 92 90 12 9 Women's Health 6 3 0 (3) Consumer Segment Worldwide 49% 46 10% 7 Worldwide 16% 13 9% 6 1) The calculation for 2007 pro-forma growth includes the consumer products acquired from Pfizer Inc. on December 20, 2006, and excludes Johnson & Johnson divestitures related to that transaction for the full year.


